Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibuprofen derivatives | 518 | 53716-49-7 |
None
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.51 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.90 hours | Lombardo F, Berellini G, Obach RS |
| BA (Bioavailability) | 90 % |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.716 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.642 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 112.980 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 15.488 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.360 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.820 | % | High | 1 |
| herg | hERG pIC50 | 4.397 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 7.031 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.105 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.470 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 58 | |||
| kinase-selectivity-class | ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,MAP2K6,MAPK7,TTK | 8 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 11.641 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 37.757 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 1.430 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.694 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.250 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 6.934 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 37.010 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.400 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 862.979 | uM | High | 1 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 31, 1987 | FDA | ROCHE |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D011838 | Radiation-Sensitizing Agents |
| MeSH PA | D017319 | Photosensitizing Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35544 | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor |
| CHEBI has role | CHEBI:47868 | photosensitizing agent |
None
| Species | Use | Relation |
|---|---|---|
| Dogs | Postoperative pain associated with soft tissue and orthopedic surgery | Indication |
| Dogs | Pain and inflammation associated with osteoarthritis | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Rimadyl Sterile Injectable Solution | Zoetis Inc. | 1 |
| Rimadyl Caplets | Zoetis Inc. | 1 |
| Rimadyl Chewable Tablets | Zoetis Inc. | 1 |
| Carprofen Caplets, Novox Caplets | Dechra Veterinary Products LLC | 1 |
| Vetprofen | Belcher Pharmaceuticals Inc. | 1 |
| Carprofen | Dechra Veterinary Products LLC | 1 |
| Carprieve Caplets | Norbrook Laboratories, Ltd. | 1 |
| Carprieve Injection | Norbrook Laboratories, Ltd. | 1 |
| Carprofen Sterile Injectable Solution | Dechra Veterinary Products LLC | 1 |
| quellin | Elanco US Inc. | 1 |
| Carprofen Chewable Tablets | Dechra Veterinary Products LLC | 1 |
| Carprofen Flavored Tablets | Belcher Pharmaceuticals Inc. | 1 |
| Carprofen Injection | Accord Healthcare Inc. | 1 |
| Carprieve Chewable Tablets | Norbrook Laboratories, Ltd. | 1 |
| Carprofen Tablets | Dechra Veterinary Products LLC | 1 |
| Carprofen Chewable Tablets | Cronus Pharma Specialities India Private Limited | 1 |
| Carprofen Tablets | Dechra Veterinary Products LLC | 1 |
| CARPROFEN Chewable Tablets | Felix Pharmaceuticals Pvt. Ltd. | 1 |
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.53 | acidic |
| pKa2 | 11.59 | acidic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 7 | CHEMBL | CHEMBL | |||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 4.88 | CHEMBL | |||||
| Complement C5 | Secreted | Kd | 6.24 | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 4.89 | CHEMBL | |||||
| Fatty-acid amide hydrolase 1 | Enzyme | IC50 | 4.10 | CHEMBL |
| ID | Source |
|---|---|
| D03410 | KEGG_DRUG |
| 20343 | RXNORM |
| C0054827 | UMLSCUI |
| CHEBI:364453 | CHEBI |
| CHEMBL1316 | ChEMBL_ID |
| DB00821 | DRUGBANK_ID |
| C007005 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2581 | PUBCHEM_CID |
| 7141 | IUPHAR_LIGAND_ID |
| 3980 | INN_ID |
| FFL0D546HO | UNII |
| 125710006 | SNOMEDCT_US |
| 424611009 | SNOMEDCT_US |
| 4025237 | VANDF |
| 005102 | NDDF |
None